Lite Strategy LITS
NASDAQ LITS
$0.99 +0.05 (+4.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Accumulated Expenses (2011 - 2026)

Lite Strategy (LITS) posted quarterly Accumulated Expenses of $699000.0 for Q1 2026, down 34.12% year-over-year from $1.1 million in Q1 2025, and down 8.03% quarter-over-quarter from $760000.0 in Q4 2025.

Lite Strategy (LITS) Accumulated Expenses (2011 - 2026) Analysis & Trends

Lite Strategy's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $699000.0 for Q1 2026.

  • In Q1 2026, Accumulated Expenses fell 34.12% year-over-year to $699000.0; the TTM figure through Mar 2026 stood at $699000.0 (down 34.12% YoY), while the FY2025 annual figure was $873000.0, down 69.05% from the prior year.
  • Accumulated Expenses for Q1 2026 stood at $699000.0, down from $760000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $16.3 million in Q1 2023, with the low at $260000.0 in Q3 2025.
  • The 5-year median for Accumulated Expenses is $4.3 million (2023), against an average of $5.1 million.
  • The sharpest annual moves came in 2023 and 2025: Accumulated Expenses surged 65.42% in 2023, then plunged 86.29% in 2025.
  • Lite Strategy's Accumulated Expenses stood at $14.3 million in 2022, then plunged by 60.65% to $5.6 million in 2023, then tumbled by 73.85% to $1.5 million in 2024, then sank by 48.51% to $760000.0 in 2025, then declined by 8.03% to $699000.0 in 2026.
  • Business Quant data shows LITS's Accumulated Expenses at $699000.0 in Q1 2026, $760000.0 in Q4 2025, and $260000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Lite Strategy 35.71 Mn 28.17 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 699,000.00
Dec 31, 2025 760,000.00
Sep 30, 2025 260,000.00
Jun 30, 2025 873,000.00
Mar 31, 2025 1.06 Mn
Dec 31, 2024 1.48 Mn
Sep 30, 2024 1.90 Mn
Jun 30, 2024 2.82 Mn
Mar 31, 2024 5.39 Mn
Dec 31, 2023 5.65 Mn
Sep 30, 2023 4.29 Mn
Jun 30, 2023 7.19 Mn
Mar 31, 2023 16.26 Mn
Dec 31, 2022 14.35 Mn
Sep 30, 2022 9.22 Mn
Jun 30, 2022 4.35 Mn
Mar 31, 2022 10.08 Mn
Dec 31, 2021 9.77 Mn
Sep 30, 2021 6.10 Mn
Jun 30, 2021 3.51 Mn